Chinese biopharmaceutical firm Gensciences has raked in a total of over 800 million yuan ($123.6 million) through its Series A and Series B rounds of financing as the life science sector is gaining more traction during the global health crisis.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
